Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Autor: Al-Sawaf, Othman, Zhang, Can, Jin, Hyun Yong, Robrecht, Sandra, Choi, Yoonha, Balasubramanian, Sandhya, Kotak, Alex, Chang, Yi Meng, Fink, Anna Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Kreuzer, Karl-Anton, Chyla, Brenda, Paulson, Joseph N., Pallasch, Christian P., Frenzel, Lukas P., Peifer, Martin, Eichhorst, Barbara, Stilgenbauer, Stephan
Předmět:
Zdroj: Nature Communications; 10/23/2023, Vol. 14 Issue 1, p1-1, 1p
Abstrakt: The original version of this article contained an error in Figure 1d, in which the I y i axis was labeled "Cum Progression-free Survival" rather than "Cum Survival". Correction to: I Nature Communications i https://doi.org/10.1038/s41467-023-37648-w, published online 18 April 2023 The original version of this article contained an error in the spelling of the author "Joseph N. Paulson", which was incorrectly given as "Joe Paulson". [Extracted from the article]
Databáze: Complementary Index
Externí odkaz: